Evidence map›Paper›PMID 34565386›Full record

ArticleJournal of translational medicine2021

Feasibility and utility of MRI and dynamic

Heidi Espedal, Hege F Berg, Tina Fonnes, Kristine E Fasmer, Camilla Krakstad, Ingfrid S Haldorsen

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. CXCR4-targeted PET imaging of glioblastoma using [EJNMMI radiopharmacy and chemistry · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Heidi EspedalDepartment of Clinical Medicine, University of Bergen, 5021, Bergen, Norway. heidi.espedal@uib.no.ORCID 0000-0002-0190-8999
Hege F BergCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.
Tina FonnesCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.
Kristine E FasmerDepartment of Clinical Medicine, University of Bergen, 5021, Bergen, Norway.
Camilla KrakstadCentre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5021, Bergen, Norway.
Ingfrid S HaldorsenDepartment of Clinical Medicine, University of Bergen, 5021, Bergen, Norway.
Haukeland University Hospital · NO

Funding

Helse Vest F-10221Kreftforeningen 190202-2017Norges Forskningsråd 273280Norges Forskningsråd 311350Trond Mohn Foundation BFS2018TMT06
6 · The paper itself

Abstract

backgroundPelvic magnetic resonance imaging (MRI) and whole-body positron emission tomography-computed tomography (PET-CT) play an important role at primary diagnostic work-up and in detecting recurrent disease in endometrial cancer (EC) patients, however the preclinical use of these imaging methods is currently limited. We demonstrate the feasibility and utility of MRI and dynamic

methods18 O-PDX mice (grade 3 endometrioid EC, stage IIIC1), selectively underwent weekly T2-weighted MRI (total scans = 32), diffusion-weighted MRI (DWI) (total scans = 9) and dynamic

resultsTumors with large tumor volumes (vMRI) had higher metabolic activity (MTV and TLG) in a clear linear relationship (r

conclusionPreclinical imaging mirroring clinical imaging methods in EC is highly feasible for monitoring tumor progression and treatment response in the present orthotopic organoid mouse model.

Indexed as

Endometrial NeoplasmsFluorodeoxyglucose F18AnimalsFeasibility StudiesFemaleHumansMagnetic Resonance ImagingMiceOrganoidsPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsTumor BurdenFluorodeoxyglucose F18RadiopharmaceuticalsDynamic PETEndometrial cancerMultimodal imagingOrganoid-PDX modelsPreclinical imagingTranslational imaging

Identifiers

PMID34565386
PMCPMC8474962
OpenAlexW3162608665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.